
At the second edition of Next-Gen LabCon, experts discussed the transformative impact of AI, ML, and RPA in pharmaceutical R&D. Panelists emphasized the benefits and risks of these technologies, the necessity for human expertise, and the importance of robust regulatory frameworks. Key topics included ethical concerns, human-machine interaction, and the role of digital technologies in enhancing research processes. The panel underscored the need for precise guidelines from regulators like the FDA to ensure the validation and proper use of AI and ML in the industry.
Like
Save
Share